Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

Back to Search
Print
Bookmark Trial

NCT00770289

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Haidari, Athens, 12461, Greece
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients

- 18-75 years old

- Patients diagnosed with MDD according to DSM IV without psychotic symptoms

- HAM-D17 > or = 18 on inclusion

- Patients receiving treatment for the first time or changing treatment based on their doctor's decision

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with potentially problematic compliance


- Subjects participating in an interventional trial within the last 3 months

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Major Depressive DisorderSertraline vs. Venlafaxine XR
NCT00179283
  1. Nashville, Tennessee
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderBrain Imaging Techniques That Predict Antidepressant Responsiveness
NCT00909155
  1. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderA Study of MD-120 in Patients With Depression
NCT04345471
  1. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Major Depressive DisorderNeurocognition and Work Productivity in Major Depressive Disorder (MDD)
NCT01468610
  1. Vancouver, British Columbia
ALL GENDERS
19 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Official Title Open Label, Observational, Non-interventional Study for the Evaluation of Remission Rates in Patients With MDD Under Treatment With Various Anti-depressives
Brief Summary Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7 questionnaires and the comparison of those questionnaires.
Detailed Description 12 weeks random
Study Type Observational
Study Design Observational Model: Cohort
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients diagnosed with MDD who are either changing treatment or have never received treatment.
Condition Major Depressive Disorder
Intervention Other: Cohort
Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
Study Groups/Cohorts Single group
Intervention: Other: Cohort
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 15, 2009)		851
Original Estimated Enrollment
 (submitted: October 8, 2008)		1000
Actual Study Completion Date December 2009
Actual Primary Completion Date December 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Outpatients
  • 18-75 years old
  • Patients diagnosed with MDD according to DSM IV without psychotic symptoms
  • HAM-D17 > or = 18 on inclusion
  • Patients receiving treatment for the first time or changing treatment based on their doctor's decision

Exclusion Criteria:

  • Subjects with potentially problematic compliance
  • Subjects participating in an interventional trial within the last 3 months
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Greece
Removed Location Countries  
 
Administrative Information
NCT Number NCT00770289
Other Study ID Numbers 0600B-102374
B2411003 ( Other Identifier: Pfizer )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2012